Debre Berhan University Institutional Repository

Immunological Treatment Failure Among Adult Patients Receiving Highly Active Antiretroviral Therapy in East Africa: A Systematic Review and Meta-Analysis

Show simple item record

dc.contributor.author Getenet, Dessie
dc.contributor.author Henok, Mulugeta
dc.contributor.author Fasil, Wagnew
dc.contributor.author Abriham, Zegeye
dc.contributor.author Dessalegn, Kiross
dc.contributor.author Ayenew, Negesse
dc.contributor.author Yared, Asmare Aynalem
dc.contributor.author Temsgen, Getaneh
dc.contributor.author Alison, Ohringer
dc.contributor.author Sahai , Burrowes
dc.date.accessioned 2021-09-13T07:38:58Z
dc.date.available 2021-09-13T07:38:58Z
dc.date.issued 2019-10-30
dc.identifier.citation https://doi.org/10.1186/s41256-019-0120-4 en_US
dc.identifier.uri http://etd.dbu.edu.et:80/handle/123456789/669
dc.description.abstract Background: Minimizing antiretroviral treatment failure is crucial for improving patient health and for maintaining long-term access to care in low-income settings such as eastern Africa. To develop interventions to support adherence, policymakers must understand the extent and scope of treatment failure in their programs. However, estimates of treatment failure in eastern Africa have been variable and inconclusive. Objective: This systematic review and meta-analysis sought to determine the pooled prevalence of immunological failure among adults receiving antiretroviral therapy in eastern Africa. Methods: We performed a systematic search of the PubMed, Google Scholar, Excerpta Medica Database, and the World Health Organization's Hinari portal (which includes the Scopus, African Index Medicus, and African Journals Online databases) databases. Unpublished studies were also accessed from conference websites and university repositories. We used Stata version 14 for data analysis. The Cochrane Q test and I 2 test statistic were used to test for heterogeneity across the studies. Due to high levels of heterogeneity, a random effects model was used to estimate the pooled prevalence of immunological failure. Begg and Egger tests of the intercept in the random effects model were used to check for publication bias. Results: After removing duplicates, 25 articles remained for assessment and screening. After quality screening, 15 articles were deemed eligible and incorporated into the final analysis. The average pooled estimate of immunological treatment failure prevalence was found to be 21.89% (95% CI, 15.14-28.64). In the subgroup analysis conducted by geographic region, the pooled prevalence of immunological treatment failure in Ethiopia was 15.2% (95% CI, 12.27-18.13) while in Tanzania it was 53.93% (95% CI, 48.14-59.73). Neither the results of Egger test or Begg tests suggested publication bias; however, on visual examination, the funnel plot appeared asymmetric. The large heterogeneity across the studies could be explained by study country. Conclusion: Immunological treatment failure among patients receiving antiretroviral therapy in eastern Africa was high, and greater than previously reported. The relatively low rates of treatment failure found in Ethiopia suggest that its health extension program should be studied as a model for improving adherence in the region. (Curr Ther Res Clin Exp. 2021; 82:XXX-XXX) © 2021 Elsevier HS Journals, Inc. en_US
dc.language.iso en en_US
dc.relation.ispartofseries Global Health Research and Policy volume 4(32); 2019;
dc.subject Antiretroviral therapy; Eastern Africa; HIV; Immunological; Treatment failure. en_US
dc.title Immunological Treatment Failure Among Adult Patients Receiving Highly Active Antiretroviral Therapy in East Africa: A Systematic Review and Meta-Analysis en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DBU-IR


Browse

My Account